LivaNova (LIVN) Stock Price, News & Analysis

Company Overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $42.44 to $43.61
• 50-Day Range: $33.85 to $45.23
• 52-Week Range: $32.48 to $61.94
• Volume: 292,346 shs
• Average Volume: 651,488 shs
• Market Capitalization: $2.34 billion
• P/E Ratio: 102.45
• Dividend Yield: N/A
• Price Target: $59.29
• Consensus Rating: Buy

LivaNova Stock Analysis - MarketRank™

LivaNova scored higher than 75% of companies evaluated by MarketBeat, and ranked 254th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

LivaNova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

LivaNova has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.18%

Earnings Growth

Earnings for LivaNova are expected to grow by 10.18% in the coming year, from $2.85 to $3.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LivaNova is 102.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.21.

Price to Earnings Ratio vs. Sector

The P/E ratio of LivaNova is 102.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.06.

Price to Book Value per Share Ratio

LivaNova has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.80% of the float of LivaNova has been sold short.

Short Interest Ratio / Days to Cover

LivaNova has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LivaNova has recently increased by 14.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LivaNova does not currently pay a dividend.

Dividend Growth

LivaNova does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.80% of the float of LivaNova has been sold short.

Short Interest Ratio / Days to Cover

LivaNova has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LivaNova has recently increased by 14.44%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.39

News Sentiment

LivaNova has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for LivaNova this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for LIVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LivaNova insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.29% of the stock of LivaNova is held by insiders.

Percentage Held by Institutions

97.64% of the stock of LivaNova is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LIVN Stock Analysis - Frequently Asked Questions

How have LIVN shares performed this year?

LivaNova's stock was trading at $46.31 at the start of the year. Since then, LIVN stock has decreased by 7.0% and is now trading at $43.05.
View the best growth stocks for 2025 here.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings results on Wednesday, May, 1st. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.28. The firm's revenue for the quarter was up 12.0% compared to the same quarter last year.
Read the conference call transcript.

Who are LivaNova's major shareholders?

LivaNova's top institutional shareholders include Primecap Management Co. CA (8.45%), Vanguard Group Inc. (4.89%), Millennium Management LLC (3.79%) and AQR Capital Management LLC (2.88%). Insiders that own company stock include Damien Mcdonald, Daniel Jeffrey Moore and Francesco Bianchi.
View institutional ownership trends.

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LivaNova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LivaNova investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/01/2024
• Today: 5/30/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LIVN
• CIK: 1639691
• Web: www.livanova.com
• Phone: 442033250660
• Fax: 281-218-9332
• Employees: 2,900
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $59.29
• High Stock Price Target: $64.00
• Low Stock Price Target: $55.00
• Potential Upside/Downside: +37.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.09)
• Trailing P/E Ratio: 102.79
• Forward P/E Ratio: 15.15
• P/E Growth: N/A
• Net Income: $17.55 million
• Net Margins: 1.91%
• Pretax Margin: -5.03%
• Return on Equity: 13.81%
• Return on Assets: 7.07%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 3.37
• Quick Ratio: 2.87

Sales & Book Value

• Annual Sales: $1.28 billion
• Price / Sales: 1.85
• Cash Flow: $3.87 per share
• Price / Cash Flow: 11.15
• Book Value: $23.72 per share
• Price / Book: 1.82

Miscellaneous

• Outstanding Shares: 54,526,000
• Free Float: 54,154,000
• Market Cap: $2.35 billion
• Optionable: Optionable
• Beta: 0.84